Apellis Pharmaceuticals, Inc.
APLS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.31 | 0.49 | 0.28 | -0.06 |
| FCF Yield | -2.23% | -8.38% | -9.39% | -14.14% |
| EV / EBITDA | -25.96 | -13.86 | -8.18 | -4.87 |
| Quality | ||||
| ROIC | -23.27% | -94.82% | -99.50% | -71.15% |
| Gross Margin | 84.93% | 85.25% | 92.53% | 92.19% |
| Cash Conversion Ratio | 0.44 | 1.13 | 0.79 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 118.00% | 81.29% | -32.99% | – |
| Free Cash Flow Growth | 85.18% | -15.57% | 8.68% | -240.08% |
| Safety | ||||
| Net Debt / EBITDA | -0.38 | 0.49 | 0.71 | 0.59 |
| Interest Coverage | -4.08 | -17.48 | -18.23 | -40.50 |
| Efficiency | ||||
| Inventory Turnover | 1.45 | 0.40 | 0.07 | 0.32 |
| Cash Conversion Cycle | 259.73 | 869.01 | 3,170.07 | 11.67 |